W
WAVEMAN · COMPANY
CAPR · Capricor Therapeutics, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475
← ALL COMPANIES

CAPR

CAPRICOR THERAPEUTICS, INC.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001133869
SEC FILINGS☆ WATCH
INSIDER NET · 180D
-$8.4M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
104
13F, latest reported quarter
REVENUE GROWTH
-100.0%
XBRL, annual
NET MARGIN
-
CONVERSIONS · 180D
17
codes C/M, not in net · $1.1M priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$8.4M over 180 days
-$1.5M over 90 days
below 83% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
104 funds added or opened last quarter
more than 67% of Pharma & Biotech
REVENUE
-100.0% year over year
the lowest in Pharma & Biotech
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
27.5% of shares outstanding short · 2.1 days to cover · settled 2026-07-31
more than 99% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$8.4M across 3 people in 180 days.
104 funds added or opened positions in the latest 13F quarter, of 172 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +46.6%
+46.6%12M
-39%+127%+292%+458%2025-092025-102025-122026-032026-052026-072026-09 2026-03-31 · Sabar Karimah Es sold $1.8M2026-04-01 · Sabar Karimah Es sold $1.7M2026-05-01 · Krasney Karen sold $792.5K2026-05-01 · Bergmann Anthony sold $792.5K2026-03-31 · Bergmann Anthony sold $753.2K2026-03-31 · Krasney Karen sold $753.0K2026-06-25 · Krasney Karen sold $732.2K2026-06-25 · Bergmann Anthony sold $732.2K2026-04-02 · Sabar Karimah Es sold $240.9K2026-06-22 · Krasney Karen sold $15.0K2026-06-22 · Bergmann Anthony sold $15.0K2026-06-24 · Krasney Karen sold $12.0K2026-06-24 · Bergmann Anthony sold $12.0K
INSIDER SELL
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
The complete filing record, in one place.
The record shows a net $8.4M sold by insiders over 180 days, 104 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, CAPRICOR THERAPEUTICS, INC. insiders sold a net $8.4M of stock across 24 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER
FILED
SHARES
VALUE
Krasney Karen
EVP, GENERAL COUNSEL
SELL
2026-06-25
24,100.0
$732.2K
Bergmann Anthony
CHIEF FINANCIAL OFFICER
SELL
2026-06-25
24,100.0
$732.2K
Krasney Karen
EVP, GENERAL COUNSEL
SELL
2026-06-24
400.0
$12.0K
Bergmann Anthony
CHIEF FINANCIAL OFFICER
SELL
2026-06-24
400.0
$12.0K
Krasney Karen
EVP, GENERAL COUNSEL
SELL
2026-06-22
500.0
$15.0K
24 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 19 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
BlackRock, Inc.
4,145,061.0 sh
$99.8M
TANG CAPITAL MANAGEMENT LLC
4,099,900.0 sh
$98.7M
MONTANOVA CAPITAL, LLC
4,092,784.0 sh
$98.6M
STATE STREET CORP
3,397,150.0 sh
$81.8M
VANGUARD CAPITAL MANAGEMENT LLC
2,297,674.0 sh
$55.3M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Invesco Dorsey Wright Healthcare Momentum ETF
$2.7M POSITION · AS OF 2026-04-30
2.3%
Virtus Biotech Clinical Trials Etf
$356.1K POSITION · AS OF 2026-04-30
1.0%
Select Pharmaceuticals Portfolio
$10.9M POSITION · AS OF 2026-02-28
0.7%
Dunham Small Cap Growth Fund
$412.9K POSITION · AS OF 2026-04-30
0.5%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$35.6M POSITION · AS OF 2026-03-31
0.5%
PROFUND VP BIOTECHNOLOGY
$194.8K POSITION · AS OF 2026-03-31
0.5%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Executive pay vs shareholder return
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$3.5M
$7.2M
$1.5M
+648%
2024
$1.5M
$5.1M
$899.9K
+258%
2023
$774.3K
$1.2M
$740.6K
+27%
2022
$1.3M
$2.2M
$796.1K
+32%
2021
$1.8M
$1.2M
$702.1K
-15%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$0$22.3M$25.2M$2.6M
OPERATING INCOME$-108.1M$-42.6M$-24.1M$-29.7M
NET INCOME$-105.0M$-40.5M$-22.3M$-29.0M
EPS (DILUTED)-2.26-1.15-0.83-1.18
OPERATING CASH FLOW$-69.8M$-40.0M$-25.6M$4.9M
CASH$287.8M$11.3M$14.7M$9.6M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-04 ALL SYSTEMS LIVE FOR MACHINES →